Hematology / Oncology CE Activities

Navigating the Frontier of Hematologic Malignancy Therapies. Series of 5 Modules

3.00 CE Credit(s)

Cell-Free DNA Potential in Guiding Therapies and Q&A – Module 5

1.00 CE Credit(s)

PROTACs: A Paradigm Shift in Drug Discovery – Module 3

0.50 CE Credit(s)

Novel ADC Target Hunting in Pediatric AML – Module 4

0.50 CE Credit(s)

Approaches Beyond Classic CAR T-Cells – Module 2

0.50 CE Credit(s)

Bispecific Antibodies Latch Onto Advances – Module 1

0.50 CE Credit(s)

Taking Stock of the Evolving Treatment Landscape for Acute GvHD in HSCT: Proceedings from a Clinical Olympics℠

1.00 CE Credit(s)

Exploiting BCMA in the Treatment of Multiple Myeloma: How Could Bispecific Antibodies and T-Cell Engagement Impact Relapsed/Refractory Disease? Proceedings from a Clinical Olympics℠

1.00 CE Credit(s)

Hybrid Satellite Symposium at the 49th Annual Meeting of the EBMT

Immunotherapy in NMSC: Bringing the Data to Life

0.50 CE Credit(s)

Harnessing the Full Potential of Frontline Immunotherapy in Advanced NSCLC: Proceedings from a Clinical Olympics℠

1.00 CE Credit(s)

Seeing Nonmelanoma Skin Cancers Through a New Lens: The Role and Place of Immunotherapy

1.00 CE Credit(s)

Identifying Patients at Risk for Advanced NMSC: A Visual Guide

0.25 CE Credit(s)

Immunotherapy in Advanced NMSC: Treatment Selection and Collaborative Care

0.25 CE Credit(s)

Advanced NMSC: Determining Patient Candidacy for Immunotherapy

0.25 CE Credit(s)

Optimizing Frontline Immunotherapy in Advanced Non-Small Cell Lung Cancer: Program Highlights

0.75 CE Credit(s)

Nonmelanoma Skin Cancers, Immunotherapies, and Role of Dermatology Clinicians: A Care Team Forum^®

0.75 CE Credit(s)

The Road to Cures Through Immunotherapy and Precision Medicine. Series of 5 Modules

2.75 CE Credit(s)

EXPIRES: April 5, 2023

Perspectives on Optimizing Immunotherapy in Advanced BCC and CSCC

0.50 CE Credit(s)

EXPIRES: April 5, 2023

Challenging Cases: HPI Switching in BCC, Adjuvant Therapy in CSCC

0.25 CE Credit(s)

EXPIRES: April 5, 2023

Challenging Cases: BCC in HIV Infection, New Skin Lesions in Metastatic CSCC

0.25 CE Credit(s)

RMEI Presentations

Iterative Data-Driven Education for Evolving Strategies of Care in cSCC

When the Patient Voice is Heard in Education, Does the Clinician Listen?

RMEI DECISION SUPPORT AIDS

Seeing Nonmelanoma Skin Cancers Through A New Lens: The Role and Place of Immunotherapy

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.

Hematology / Oncology
Decision Support Aid

Relapsed or Refractory Chronic-Phase: CHRONIC MYELOID LEUKEMIA (CML)

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.

Hematology / Oncology
Decision Support Aid

LATEST HEMATOLOGY / ONCOLOGY ARTICLES

Latest Hematology / Oncology Articles

A Double Whammy on Gastric Cancer Risk March 30, 2023
This editorial describes the science behind a study of determinants of gastric cancer risk — in particular, an interaction between genetic variants in a specific class of genes and infection with Helicobacter pylori.
Anne Müller, Jiazhuo He
Helicobacter pylori, Homologous-Recombination Genes, and Gastric Cancer March 30, 2023
Infection with Helicobacter pylori is known to confer a risk of gastric cancer. In this study, persons who carried certain genetic variants and were infected with H. pylori had an excess risk of gastric cancer.
Yoshiaki Usui, Yukari Taniyama, Mikiko Endo, Yuriko N. Koyanagi, Yumiko Kasugai, Isao Oze, Hidemi Ito, Issei Imoto, Tsutomu Tanaka, Masahiro Tajika, Yasumasa Niwa, Yusuke Iwasaki, Tomomi Aoi, Nozomi Hakozaki, Sadaaki Takata, Kunihiko Suzuki, Chikashi Terao, Masanori Hatakeyama, Makoto Hirata, Kokichi Sugano, Teruhiko Yoshida, Yoichiro Kamatani, Hidewaki Nakagawa, Koichi Matsuda, Yoshinori Murakami, Amanda B. Spurdle, Keitaro Matsuo, Yukihide Momozawa
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer March 27, 2023
A randomized trial compared standard chemotherapy plus dostarlimab or placebo. Patients with mismatch repair–deficient tumors had 2-year progression-free survival of 61.4% with dostarlimab and 15.7% with placebo.
Mansoor R. Mirza, Dana M. Chase, Brian M. Slomovitz, René dePont Christensen, Zoltán Novák, Destin Black, Lucy Gilbert, Sudarshan Sharma, Giorgio Valabrega, Lisa M. Landrum, Lars C. Hanker, Ashley Stuckey, Ingrid Boere, Michael A. Gold, Annika Auranen, Bhavana Pothuri, David Cibula, Carolyn McCourt, Francesco Raspagliesi, Mark S. Shahin, Sarah E. Gill, Bradley J. Monk, Joseph Buscema, Thomas J. Herzog, Larry J. Copeland, Min Tian, Zangdong He, Shadi Stevens, Eleftherios Zografos, Robert L. Coleman, Matthew A. Powell, the RUBY Investigators

RMEI LIGHTNING TALKS

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.

Allergy & Immunology
2021

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.